PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-140.19%
Both yoy net incomes decline, with CRON.TO at -79.89%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
153.97%
Some D&A expansion while CRON.TO is negative at -3.73%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-220.74%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
17.45%
SBC growth while CRON.TO is negative at -12.25%. John Neff would see competitor possibly controlling share issuance more tightly.
-240.38%
Negative yoy working capital usage while CRON.TO is 424.71%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
203.29%
AR growth while CRON.TO is negative at -68.11%. John Neff would note competitor possibly improving working capital while we allow AR to rise.
-283.24%
Negative yoy inventory while CRON.TO is 14.52%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
85.52%
Lower AP growth vs. CRON.TO's 1552.32%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-428.87%
Negative yoy usage while CRON.TO is 348.42%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
79.99%
Lower 'other non-cash' growth vs. CRON.TO's 6818.23%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-4001.79%
Negative yoy CFO while CRON.TO is 290.13%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
35.72%
Some CapEx rise while CRON.TO is negative at -6.76%. John Neff would see competitor possibly building capacity while we hold back expansions.
-1345.94%
Both yoy lines negative, with CRON.TO at -135.18%. Martin Whitman sees an overall caution or integration phase for both companies’ expansions.
85.54%
Purchases growth of 85.54% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
382.44%
Liquidation growth of 382.44% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-33.52%
Both yoy lines negative, with CRON.TO at -46.23%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
61.38%
We have mild expansions while CRON.TO is negative at -14.18%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-2757.96%
We cut debt repayment yoy while CRON.TO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-100.00%
Negative yoy issuance while CRON.TO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.